GNI files to take liver failure drug into Chinese trials
This article was originally published in Scrip
Executive Summary
The GNI Group subsidiary Shanghai Genomics has applied to take its third pipeline project into clinical development in China, filing an IND with the Shanghai FDA to begin clinical trials with the hepatic failure therapy F573.